228
Participants
Start Date
August 1, 2016
Primary Completion Date
July 15, 2017
Study Completion Date
October 31, 2017
Sofosbuvir and Velpatasvir
All patients received a generic version of VEL/SOF fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
Ribavirin
Patients with decompensated cirrhosis (Child-Pugh B or C), received weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight \< 75 mg) for 12 weeks.
National Taiwan University Hospital, Yun-Lin Branch, Douliu
National Taiwan University Hospital, Taipei
National Taiwan University Hospital
OTHER